drugset / Trial / NCT03071874
Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas
Phase 2
Unknown
28 enrolled
Massachusetts General Hospital
AstraZeneca · collabNational Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
This research study is studying a chemotherapy as a possible treatment for Meningiomas (recurrent). The study intervention involved in this study is: --AZD2014 (vistusertib)
Timeline
- Start
- 2017-10-17
- Primary completion
- 2022-06-30
- Completion
- 2024-07-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vistusertib | Small molecule | — | Oral |